Navigation Links
Viral protein influences key cell-signaling pathway

New research shows that a protein produced by a cancer-causing virus influences a key signaling pathway in the immune cells that the virus infects. This stimulates the cells to divide, helping the virus spread through the body.

The study, led by researchers at Ohio State University, examined the human T lymphotropic virus type 1 (HTLV-1) and a protein that it produces called p12.

The research is published in the April issue of the journal AIDS Research and Human Retroviruses.

The study found that p12 increases the activity of an important gene in host cells. That gene controls production of a cell protein called p300. The p300 protein, in turn, controls a variety of other genes in many types of cells, including T lymphocytes, the cells that HTLV-1 infects.

The findings might help scientists better understand how HTLV-1 maintains its lifelong infection and how the normal immune cells that "remember" a vaccination or an infection can survive for years or even decades.

"The p300 protein is an important central regulator of gene activity in lymphocytes and many other kinds of cells," says Michael Lairmore, professor and chair of veterinary biosciences and a member of the OSU Comprehensive Cancer Center ?Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. "We were surprised to see p300 show-up among the many genes affected by this viral protein."

HTLV-1 infects an estimated 15 to 20 million people worldwide. In about five percent of them, the infection will lead to adult T cell leukemia or lymphoma (ATLL). ATLL is an aggressive disease characterized by a long latent period and the proliferation of T lymphocytes. The virus is spread by sexual activity, by contact with infected blood and by infected women to children through breast milk.

HTLV-1, like its cousin HIV, inserts its genetic information permanently into the DNA of a T lymphocyte and remains there for the life of the cell. HTLV-1 infecti
'"/>

Source:Ohio State University


Page: 1 2 3

Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
3. Viral protein helps infected T cells stick to uninfected cells
4. Viral fitness explains different resistance patterns to aids drugs
5. Viral genetic differences are possible key to HIV dementia
6. Viral hitchhiker inhibits Wolbachia bacterias ability to proliferate
7. Viral marker of human migration suspect
8. Viral protein is an effective preventative against infection
9. New, automated tool successfully classifies and relates proteins in unprecedented way
10. New binding target for oncogenic viral protein
11. Controversial drug shown to act on brain protein to cut alcohol use

Post Your Comments:
(Date:11/23/2009)...RE, Calif. - By producing some of the highest reso...faces, scientists have a deeper understanding how ...research may lead to a new treatment for kidney st...ppears in the Nov. 23 online edition of the journa... , explores how peptides interact with mineral sur...
(Date:11/23/2009)...MINGHAM, Ala. A new study by University of Alabam...mass index (BMI) and co-existing medical condition...ival observed among African-Americans compared to ...s published online Nov. 23 in Cancer , a journal ...dicates that although BMI and co-morbidity are ind...
(Date:11/23/2009)...GN, Ill. Two new studies reveal in unprecedented ...ules to assemble new proteins and guide them towar...es used molecular dynamics flexible fitting (MDFF)...wo prominent molecular partners. , The first st...iences , concerns the intimate signaling between t...
Breaking Biology News(10 mins):Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 2Scientists watch as peptides control crystal growth with 'switches, throttles and brakes' 3Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 1Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 2Kensey Nash Announces Agreement to Acquire Rights to OsseoFit Product 13449 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 1Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 2Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 3Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 4Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 5Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 6Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results 13447 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 1Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 2Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 3Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 4Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 5Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 6Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 7Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 8Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 9Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 10Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 11Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 12Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 13Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 14Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 15Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 16Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 17Warner Chilcott Reports Operating Results for the Quarter Ended June 30 2009 and Updates 2009 Full Year Guidance 53933 18
...09-Oakland, Calif.- Children,s Hospital & Research...n the country to use groundbreaking technology tha... pediatric hospitals. This new method uses smart-c... or credit cards at the supermarket or gas station... starts with a respiratory therapist who takes a t...
...M, N.C. A discovery made by researchers at Wake F... mice may help explain how some people without a g...disorder. , In a study published this month in th...yne W. Godwin, Ph.D., a professor of neurobiology ...at a gene, already known to predispose people who ...
...ler University and the Institute for Advanced Stud...tiative in biology supported by a $10 million gift...y. The initiative, which builds on the complementa...will involve biologists, mathematicians, physicist...nd theoretical approaches to biological problems. ...
Other Biology News:Children's Hospital Oakland is first pediatric hospital to use 'laboratory-on-a-card' technology 2Researchers discover that gene switches on during development of epilepsy 2Researchers discover that gene switches on during development of epilepsy 3$10 million Simons Foundation gift supports new initiative with Institute for Advanced Study 2
(Date:11/24/2009)...ntly approved the Promega PowerPlex 16 HS System f...ing DNA records for the National DNA Index System....) -- The FBI recently approved the Promega PowerP...ticipating in, or generating DNA records for, the ...ontains more than seven million profiles and has a...
(Date:11/24/2009)...irstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),thegl...cedthatithassubmittedaMAAtotheEuropeanMedicinesAge...menttherapyindevelopment,forthetreatmentofType1Gau...velaglucerasealfathathasbeensubmitted,withprevious...edonaglobalsupplyshortageofthecurrentlyapprovedand...
(Date:11/24/2009)...ire/--HealthRoboticstodayannounced,thatithasformed...tors.ThisrecentlyformedToronto-basedcompanywillope...arket,install,andsupport,HealthRobotics,i.v.Roomof...ductofferingsi.v.STATION(TM),i.v.SOFT(TM),andOMM(T...nceonan"asneeded,basis"toitsstrategicpartnershipsw...
(Date:11/24/2009)...tCall/--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CT...yHealthCareConference.TheconferencewillbeheldDecem...presentonTuesday,December1at11:00a.m.EasternTimein...tionwillbeavailableat www.celltherapeutics.com ,an...erJaffrayHealthCareConference,NewYorkPalaceHotel,H...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
... (Nasdaq: DCTH ) today announced the appointment...rectors. Dr. Stoll is Executive Chairman of Corte...ology company specializing in the treatment of cen... http://www.newscom.com/cgi-bin/prnh/20081118/NY46...toll worked as a consultant to several east coast ...
...orporation,(Nasdaq: PRXL ), a leading global bio...hat it has established an alliance with Safe Imple...onal, the world,s largest network of,clinical site...oke. Through,this alliance, PAREXEL,s clients bene...r sites located in 40 countries, which are dedicat...
...armaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) an...ons following the failure of the Bicifadine Phase ...employment of 9 employees,representing 75% of its ...sible for seeking potential assets or a company to...on and/or disposition of XTL,s assets. , Cau...
Other Biology Technology:Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 2PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 3PAREXEL Establishes Alliance with SITS Network of Clinical Sites Specializing in Stroke Studies 4
... a base medium for preparation of minimal and synt...ulfate but does not contain amino acids. Both bulk... Each pouch contains reagents to prepare 500 ml of...r S. cerevisiae media. Store at 15C to 30C. Guaran...
...ons are cytopathic effect inhibition assays, also ...tion assay measures the antibody's ability to neut...pes include; tissue culture supernatents; serum an...t is defined as the quantity of interferon require...
Rabbit Anti-Shigella Polyclonal Antibody, Unconjugated from GeneTex
...dy is a mouse monoclonal antibody (IgG1) with high...(GST) domain from S. japonicum . This purified ant...ntaining the GSTTag sequence expressed in E. coli ...nslation systems by Western blotting, immunofluore...
Biology Products: